Inhaled ethanolic and aqueous solutions via Respimat Soft Mist Inhaler are well-tolerated in asthma patients

Respiration

Volumn 73, Issue 4, 2006, Pages 434-440

  Patel, K R ^a   Pavia, D ^b   Lowe, L ^b   Spiteri, M ^c  

^a WESTERN INFIRMARY   (United Kingdom)

^b BOEHRINGER INGELHEIM LTD   (United Kingdom)

^c UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Hyper reactive airways; Paradoxical bronchoconstriction; Respimat; Soft Mist Inhaler

Indexed keywords

ALCOHOL; BENZALKONIUM CHLORIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; EDETIC ACID; SODIUM CHLORIDE;

ADULT; AQUEOUS SOLUTION; ARTICLE; ASTHMA; BIOSAFETY; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE VARIABILITY; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WHEEZING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ASTHMA; BRONCHIAL HYPERREACTIVITY; EQUIPMENT DESIGN; ETHANOL; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PLACEBOS; SMOKING; SOLUTIONS; WATER;

EID: 33745202881     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089426     Document Type: Article

References (25)

1. Cocchetto DM, Sykes RS, Spector S: Paradoxical bronchoconstriction after use of inhalation aerosols: a review of the literature. J Asthma 1991;28:49-53.
2. Eckert B, Armstrong JG, Mitchell CA: Paradoxical bronchoconstriction in patients with stable asthma. Med J Aust 1993;159:566.
3. Nicklas RA: Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol 1990;85:959-964.
4. van Bever HP, Desager KN: Paradoxical bronchoconstriction in wheezing infants after nebulized ipratropium bromide. BMJ 1990;300:397-398.
5. O'Callaghan C, Milner AD, Swarbrick A: Paradoxical deterioration in lung function after nebulised salbutamol in wheezy infants. Lancet 1986;ii:1424-1425.
6. Shaheen MZ, Ayres JG, Benincasa C: Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients. Eur Respir J 1994;7:2160-2164.
7. Koehler D, Pavia D, Dewberry H, Hodder R: Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat® Soft Mist™ Inhaler: results of phase II single-dose crossover studies. Respiration 2004;71:469-476.
8. Miszkiel KA, Beasley R, Rafferty P, Holgate ST: The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Pharmacol 1988;25:157-163.
9. Zhang YG, Wright WJ, Tam WK, Nguyen-Dang TH, Salome CM, Woolcock AJ: Effect of inhaled preservatives on asthmatic subjects. 2. Benzalkonium chloride. Am Rev Respir Dis 1990;141:1405-1408.
10. Beasley R, Fishwick D, Miles JF, Hendeles L: Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy 1998;18:130-139.
11. Hochrainer D, Hölz H: Comparison of the velocities of clouds delivered from Respimat® Soft Mist Inhaler and metered dose inhalers (abstract). J Aerosol Med 2001;386:1-5.
12. Vincken W, Bantje T, Middle MV, Gerken F, Moonen D: Long-term efficacy and safety of ipratropium bromide plus fenoterol via Respimat® Soft Mist™ Inhaler (SMI) versus a pressurised metered dose inhaler in asthma. Clin Drug Invest 2004;24:17-28.
13. Kilfeather SA, Ponitz HH, Beck E, Schmidt P, Lee A, Bowen I, Hesse CH: Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ Inhaler in patients with COPD. Respir Med 2004;98:387-397.
14. von Berg A, Jeena PM, Soemantri PA, Vertruyen A, Schmidt P, Gerken F, Razzouk H: Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs a conventional metered dose inhaler plus spacer in children with asthma. Pediatr Pulmonol 2004;37:264-272.
15. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H: Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest 1998;113:957-963.
16. Hodder R, Pavia D, Dewberry H, Alexander K, Iacono P, Ponitz H, Beck E: Low incidence of paradoxical bronchoconstriction in patients with asthma and COPD during chronic use of Respimat® Soft Mist™ Inhaler. Respir Med 2005;99:1087-1095.
17. Suzuki S, Miyashita A, Matsumoto Y, Okubo T: Bronchoconstriction induced by spirometric maneuvers in patients with bronchial asthma. Ann Allergy 1990;65:315-320.
18. Mackay AD, Mustchin CP, Sterling GM: The response of asthmatic patients and normal subjects to maximum respiratory manoeuvres. Spirometry-induced bronchoconstriction. Eur J Respir Dis Suppl 1980;106:35-40.
19. Roncoroni AJ, Goldman E, Puy RJ, Mancino M: Bronchoconstriction induced by repeated forced vital capacity manoeuvres. Acta Allergol 1975;30:375-389.
20. Ainge G, Bowles JAK, McCormick SG, Richards DH, Scales MDC: Lack of deleterious effects of corticosteroid sprays containing benzalkonium chloride on nasal ciliated epithelium: in vivo results in laboratory animals. Drug Invest 1994;8:127-133.
21. Braat JP, Ainge G, Bowles JA, Richards DH, Van Riessen D, Visser WJ, Rijntjes E: The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: a combined functional, light, scanning and transmission electron microscopy study. Clin Exp Allergy 1995;25:957-965.
22. van de Donk HJ, van den Heuvel AG, Zuidema J, Merkus FW: The effects of nasal drops and their additives on human nasal mucociliary clearance. Rhinology 1982;20:127-137.
23. Kuboyama Y, Suzuki K, Hara T: Nasal lesions induced by intranasal administration of benzalkonium chloride in rats. J Toxicol Sci 1997;22:153-160.
24. Boek WM, Romeijn SG, Graamans K, Verhoef JC, Merkus FW, Huizing EH: Validation of animal experiments on ciliary function in vitro. 2. The influence of absorption enhancers, preservatives and physiologic saline. Acta Otolaryngol 1999;119:98-101.
25. Asmus MJ, Barros MD, Liang J, Chesrown SE, Hendeles L: Pulmonary function response to EDTA, an additive in nebulised bronchodilators. J Allergy Clin Immunol 2001;107:68-72.